Endogena Therapeutics Receives FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa

The FDA has granted Fast Track designation to Endogena Therapeutics' EA-2353 for the treatment of retinitis pigmentosa (RP).

EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function. This gene-independent treatment approach has potential advantages in RP, which has multiple genetic causes. EA-2353 was granted orphan drug designation by the FDA in May 2021.

Endogena Therapeutics is currently conducting a phase 1/2a dose-escalation study in collaboration with lead investigator, Mark Pennesi, MD, PhD, Professor of Ophthalmology at the Casey Eye Institute in Oregon, to examine the safety, tolerability and preliminary efficacy of EA-2353 administered by intravitreal injection in patients with RP (ClinicalTrials.gov identifier: NCT05392751). A total of 14 patients with RP due to any pathologic genetic mutation are being recruited across up to six sites in the US, and the first patient was dosed in July 2022.

The Fast Track designation will enable Endogena Therapeutics to have more frequent communications with the FDA on the development of EA-2353 and allow more rapid regulatory review of the future new drug application.

“This acknowledgement by the FDA of the potential of EA-2353 for RP gives hope for patients living with this devastating degenerative disease," Matthias Steger, PhD, CEO of Endogena, said in a company news release. "It is a significant milestone for our company, our investors, and gives recognition to our dedicated team at Endogena, who have been working for the past 6 years to reach this point.”

Endogena’s artificial intelligence-driven drug discovery platform, combined with cutting edge knowledge of molecular pathways that regulate retinal stem cells and retinal pigment epithelial cells, provides a potential new treatment paradigm to tackle degenerative conditions related to aging and genetic disorders. Beyond EA-2353, other products in Endogena’s pipeline include a treatment for dry age-related macular degeneration (AMD), which is approaching IND-enabling studies, and earlier programs in idiopathic pulmonary fibrosis (IPF) and hematopoietic recovery.